William Blair Issues Optimistic Forecast for LRMR Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities researchers at William Blair increased their Q2 2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research note issued to investors on Wednesday, April 30th. William Blair analyst M. Minter now anticipates that the company will earn ($0.50) per share for the quarter, up from their prior forecast of ($0.51). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics’ FY2025 earnings at ($1.99) EPS, Q1 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.51) EPS and FY2026 earnings at ($2.05) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Other equities research analysts have also issued reports about the stock. Truist Financial began coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 target price on the stock. HC Wainwright lifted their target price on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, March 25th. Robert W. Baird lowered their price target on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, March 25th. Guggenheim reaffirmed a “buy” rating and set a $26.00 price target on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Finally, Citigroup reiterated a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $19.63.

Larimar Therapeutics Price Performance

Shares of NASDAQ:LRMR opened at $2.10 on Monday. The firm’s 50 day simple moving average is $2.34 and its 200 day simple moving average is $4.15. Larimar Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $11.20. The company has a market capitalization of $134.46 million, a price-to-earnings ratio of -1.83 and a beta of 0.93.

Hedge Funds Weigh In On Larimar Therapeutics

Several hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its holdings in Larimar Therapeutics by 15.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock worth $24,936,000 after purchasing an additional 876,431 shares during the last quarter. Blue Owl Capital Holdings LP lifted its position in Larimar Therapeutics by 11.7% during the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after buying an additional 486,211 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Larimar Therapeutics by 23.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $8,127,000 after buying an additional 399,123 shares during the last quarter. Alyeska Investment Group L.P. grew its holdings in shares of Larimar Therapeutics by 38.6% in the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock valued at $3,808,000 after acquiring an additional 273,920 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Larimar Therapeutics by 45.1% in the 4th quarter. Renaissance Technologies LLC now owns 513,542 shares of the company’s stock valued at $1,987,000 after acquiring an additional 159,700 shares in the last quarter. 91.92% of the stock is owned by institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.